"A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack"

  • Singhal, Shaloo (Primary Chief Investigator (PCI))

Project: Research

Project Details

Project Description

HREC Reference Number: HREC/94114/Austin-2023
SSA Code: SSA/94114/MonH-2023-391694(v1)
Monash Health Local Reference: RES-23-0000-626X
StatusActive
Effective start/end date17/10/23 → 16/10/28